查詢結果分析
相關文獻
- Lymph Node Ratio as a Prognostic Determinant Following Neoadjuvant Chemoradiation and Rectal Cancer Surgery
- Prognostic Significance of Lymph Node Metastasis in Resected Colorectal Cancer
- The Impact of Metastatic Ratio to Retrieved Regional Lymph Nodes on Overall Survival in Patients with Stage III Colorectal Cancer: Focus on Numbers of Lymph Node Retrieved Less than 12
- The Use of Ratio of Metastasis in Lymph Nodes as a Predictor of Overall Survival in Colorectal Cancer
- 大腸直腸癌存活與相關預測因子探討
- The Significance of Preoperative Radiologic Lymph Node Enlargement in Early Colorectal Cancer
- 預後營養指數在結腸直腸手術的價值
- Prognostic Value of DNA Ploidy Patterns of Colorectal Adenocarcinoma
- Lymph Node Revealing Solution and Traditional 10% Buffered Formaldehyde for Detecting Lymph Nodes in Colorectal Carcinoma
- Anastomosis Leakage after Curative Resection for Mid and Low Rectal Cancer: A Poor Prognostic Factor?
頁籤選單縮合
題 名 | Lymph Node Ratio as a Prognostic Determinant Following Neoadjuvant Chemoradiation and Rectal Cancer Surgery=直腸癌經手術前化放療及手術後淋巴結比率的預後重要性 |
---|---|
作 者 | 李英瑜; 李家政; 李才宇; 吳昌杰; 饒樹文; 蕭正文; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷 期 | 24:3 2013.09[民102.09] |
頁 次 | 頁72-79 |
分類號 | 416.245 |
關鍵詞 | 直腸癌; 化放療; 預後; 淋巴結; Rectal cancer; Chemoradiation; Prognosis; Lymph node; |
語 文 | 英文(English) |
中文摘要 | 目的:這項回顧性研究目的是比較淋巴結比率在直腸癌患者接受術前化放療以及接著全直腸繫膜切除,並確定此比率是否為有用的直腸癌預後評估。方法:淋巴結比率是由同樣本內陽性淋巴結的數目除以淋巴結的總數。患者被分為3組:淋巴結比率=0,0<淋巴結比率≦0.125還有淋巴結比率>0.125。三組的人口統計學與臨床特徵之間的分佈差異由Kruskal-Wallis檢驗來進行連續變量檢測,並通過卡方檢驗或Fisher精確檢驗分類變量。生存曲線通過Kaplan-Meier法,log-rank檢驗檢測3組之間的差異。Cox比例風險回歸分別進行計算淋巴結比率和其他預後因素影響總體生存率和無病生存率的原始和調整後的危險比和95%信賴區間。統計分析由SAS軟體版本9.2進行。雙尾p值<0.05為差異有統計學意義。結果:pT分期(p值=0.019),pN分期和pTNM分期(p值均<0.001)的分佈在三組具有顯著性差異。較高分期的群體具有較高的淋巴結比率。淋巴結比率較高的患者也有更高的淋巴結檢查數量(p值=0.002),陽性淋巴結的數目較高、較大比例的淋巴血管間隙浸潤陽性(p值均<0.001)。無病生存率曲線在三組有顯著差異。生存曲線表示淋巴結比率>0.125的患者預後較其他兩組差。結論:淋巴結比率對於接受術前化放療以及接著全直腸繫膜切除的直腸癌患者的無病生存率是一個重要的預後因素。 |
英文摘要 | Purpose. The purpose of this retrospective study was to compare the lymph node ratios (LNRs) of patients with rectal cancer who underwent neoadjuvant chemoradiation followed by total mesorectal excision (TME) in order to examine the applicability of this ratio as an indicator for the prognosis of rectal cancer.Methods. Lymph node ratio refers to the number of positive lymph nodes divided by the total number of lymph nodes within a given sample. Patients were categorized into three groups: LNR=0, 0<LNR≤0.125, and LNR>0.125. Differences in demographic distributions and clinical characteristics among the groups were detected using the Kruskal-Wallis test for continuous variables as well as the Chi-square test or Fisher's exact test for categorical variables. Survival curves were constructed according to the Kaplan-Meier method using the log-rank test to detect the difference between three LNR groups. Cox's proportional hazard regression model was used to calculate crude and adjusted hazard ratios (HR), with 95% confidence intervals (CIs), regarding the influence of LNR and other prognostic factors on overall survival (OS) and disease-free survival (DFS), respectively. Statistical analysis was performed using SAS software version 9.2 (SAS Institute Inc., Cary, NC). Two-tailed p<0.05 indicated statistical significance. Results. The distributions of pT stage (p=0.019), pN stage (p<0.001), and pTNM stage (p<0.001) differed significantly among the three LNR groups. Cases of more advanced stages of the disease were observed in groups with higher LNR. Patients with higher LNR had a greater number of lymph nodes examined (p=0.002), higher number of positive lymph nodes (p<0.001), and a greater proportion of positive LVSI (p<0.001). The DFS curves among the three LNR groups differed significantly (log-rank test, p<0.0001); however, the OS curves did not reach significance (p=0.065). Survival curves indicated that patients with LNR>0.125 had a worse prognosis than patients in the other two groups. However, the differences in OS and DFS between groups with LNR=0 and 0<LNR≤0.125 were not significant.Conclusion. This study indicates that LNR is an important prognostic indicator of disease-free survival among patients who undergo neoadjuvant chemoradiation followed by TME for rectal cancer. |
本系統中英文摘要資訊取自各篇刊載內容。